In an attempt to examine and compare the effect of the two commercially available recombinant FSH on ovarian stimulation characteristics and IVF cycle outcome, we studied 264 IVF cycles in patients with a favorable prognosis a priori, 198 in patients using follitropin-alpha, and 68 in patients using follitropin-beta. Although both groups achieved a comparable number of retrieved oocytes, the use of follitropin-beta was associated with a tendency toward a lower clinical pregnancy rate (PR), and with significantly higher E(2) levels despite the use of significantly lower total gonadotropin dose.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.fertnstert.2008.08.112 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Follitropin Alpha versus Follitropin Beta in IVF/ICSI Cycle: A Retrospective Cohort Study.
Drug Des Devel Ther
October 2024
The First Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Purpose: The purpose of this study was to compare the efficacy of Follitropin alpha (Gonal-F) and Follitropin beta (Puregon) on cumulative live birth rate (CLBR), defined as the percentage of the number of patients who delivered for the first time in a single ovarian stimulation cycle and the number of patients in all oocyte retrieval cycles.
Methods: A retrospective cohort study including 2864 infertile patients who underwent ovarian stimulation with Puregon (group A, n=1313) and Gonal-F (group B, n=1551) was conducted between July 2015 and June 2021 at a university-affiliated reproductive medicine center. Reduce potential confounding factors between groups, propensity scores and multivariable logistic regression analyses were estimated to obtain unbiased estimates of outcomes.
Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France.
Eur J Obstet Gynecol Reprod Biol X
June 2024
Gedeon Richter Suisse, Chemin des Mines 2, 1202 Geneva, Switzerland.
Article Synopsis
- - The study compares the cost-effectiveness of the follitropin alfa biosimilar (Bemfola®) and its originator (Gonal-f®) in the French healthcare system, focusing on the cost per cumulative live-birth (CLB) based on real-world evidence rather than clinical trials.
- - A decision-tree cost-effectiveness model was used to analyze costs and cumulative live-birth rates after ovarian stimulation, including expenses from both fresh and frozen embryo transfers.
- - Results indicated that the biosimilar is more cost-effective, with a cost per CLB of €18,147 compared to €18,834 for the originator, leading to potential savings of €687 to €1,155 per
Follitropin Alpha for assisted reproduction: an analysis based on a non-interventional study in Greece.
Curr Med Res Opin
December 2022
Fertility Center, "Embryo A.R.T. Center", Athens, Greece.
Objective: To conduct an economic evaluation estimating the cost per live birth after controlled ovarian stimulation (COS) using Follitropin Alpha (Gonal-F), in the Greek National Health System setting. A secondary objective was to predict the live birth rateof the Fertilization (IVF) procedure.
Methods: A single arm, multi-center, prospective, non-interventional study was conducted on which economic, efficacy and safety data were collected by six of the largest IVF centers.
Follitropin alpha versus beta in a first GnRH antagonist ICSI cycle: a retrospective cohort study.
Reprod Biomed Online
October 2021
Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium; Department of Obstetrics and Gynaecology, University of Zagreb, Zagreb, Croatia. Electronic address:
Research Question: Are cumulative live birth rates (CLBR) after follitropin alpha (Ovaleap®) and follitropin beta (Puregon®) similar when used for ovarian stimulation with ICSI (intracytoplasmic sperm injection) in a first-rank gonadotrophin-releasing hormone (GnRH) antagonist protocol?
Design: Retrospective single-centre cohort study including 832 infertile patients undergoing ovarian stimulation with a daily dose of 150-225 IU FSH in their first ICSI cycle at a tertiary referral centre between July 2016 and July 2019. Of those, 349 patients used Ovaleap and 483 patients received Puregon.
Results: Baseline characteristics were not statistically different between the groups.
The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature.
Expert Rev Pharmacoecon Outcomes Res
August 2021
Department of Obstetrics and Gynecology, "Filippo Del Ponte" Hospital, University of Insubria, Varese, Italy.
: To study the impact of biosimilars in assisted reproductive treatments, we performed a review of the literature. Biosimilars are a bioequivalent chemical drug referred to the original. Their production is strongly requested in order to reduce drug cost and reduce health economic impact on national health system.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!